Jubilant Radiopharma announced today that its Radiopharmacies Division has been awarded the group purchasing agreement by Premier Inc. for its full line of radiopharmaceuticals products.
Jubilant Radiopharma announced today that its Radiopharmacies Division has been awarded the group purchasing agreement by Premier Inc. for its full line of radiopharmaceuticals products.
YARDLEY, Pa., October 25, 2019 (Newswire.com) - The Radiopharma Division of Jubilant Pharma Limited, announced today that under its Radiopharmacies business, the Company has been awarded the group purchasing agreement by Premier Inc. for its full line of radiopharmaceuticals products. The agreement becomes effective January 1, 2020, and allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for their line of radiopharmaceuticals. Additionally, Jubilant was selected as the sole-source supplier for the Premier Ascend program, which provides the Ascend members with access to enhanced value for this highly committed program.
“Jubilant is proud to be selected as a supplier by Premier to service the radiopharmaceutical needs of their members across the country,“ said Pramod Yadav, CEO, Jubilant Pharma Limited. “We have made great strides over the past few years to build a leading nuclear medicine company and are confident Premier members and their patients will benefit from the high-quality products and services to which they now have access.”
Radiopharmaceuticals are low-level radioactive drugs used by physicians. These products are carefully monitored and typically used for diagnostic purposes, in conjunction with imaging devices, to scan vital organs for diseases, but are also used as a theragnostics tool to treat certain cancers.
ABOUT SUPPLIER
About Jubilant Pharma Limited
Jubilant Pharma Limited (JPL), a company incorporated under the laws of Singapore and a wholly owned subsidiary of Jubilant Life Sciences Limited, is an integrated, global pharmaceutical company engaged in the manufacturing and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile Injectables and Non?sterile products through six USFDA approved manufacturing facilities in the U.S., Canada and India and a network of over 50 radio?pharmacies in the U.S. The Company has a team of over 4,300 multicultural people across the globe and is committed to delivering value to its customers, spread across over 75 countries. It is well recognized as a ‘Partner of Choice’ by leading pharmaceutical companies globally.
About Jubilant Radiopharma
Jubilant Radiopharma a business division of Jubilant Pharma Limited, is an industry leader focused on developing, manufacturing, commercializing and distributing high quality and sustainable diagnostic and therapeutic agents for the sole purpose of Improving Lives Through Nuclear Medicine on a global scale.
Media Contact:
Robert Sgroi
Director of Marketing & New Product Opportunities
